Essentials of European Medical Device Regulatory Affairs

End of clinical investigation (Article 77)

Temporary halt or early termination • Sponsor informs specific MS within 15 days with justification • If halted for safety reasons inform all concerned MS within 24 hours Scheduled end of the CI • End of CI = LPV unless defined otherwise in the clinical plan. • inform MS of their LPV within 15 days • Multi country study inform all MS of the LPV of all MS with 15 of the last LPV. Submit Clinical investigation report (signed by PI) and summary (suitable for the intended user) 3 months from early termination, one year from scheduled end of trial. If one year is not feasible this should be stated in the clinical plan with justification. The reports will become publically available immediately in the case of an early termination, otherwise when the device is registered or after 1 year which ever is earliest.

The Organisationfor Professionals inRegulatory Affairs

CI Adverse event reporting

Record • AEs critical to the evaluation • SAEs • Device deficiencies that might have led to an SAE • Relevant new findings Report to all concerned MS (via portal) • SAE causally related to the device, comparator or procedure • Device deficiency that might have led to SAE • Events in non EU countries involved in the CI Timeline • Without delay: an initial to allow that and follow up report

If a PMCF investigation follow marketed product reporting rules

The Organisationfor Professionals inRegulatory Affairs